Adequate pharmacotherapy of allergic rhinitis

In 2016, the percent of people in Europe suffering from allergic rhinitis is up to 28.5%. The prevalence of allergic rhinitis in the Russian Federation is from 10 to 24%, while allergic rhinitis is among the three most common diseases, after cardiovascular disease and oncology. Allergic rhinitis is characterized by sneezing, itching in the nasal cavity, nasal congestion and rhinorrhea. Intermittent allergic rhinitis is characterized by symptoms less than 4 days a week or less than 4 weeks a year. Persistent allergic rhinitis is characterized by the course of symptoms more than 4 days a week or longer than 4 weeks a year. There are mild, moderate and severe allergic rhinitis, which differ in the severity of symptoms and influence on the quality of life of the patient. Allergy caused by fungal pathogens is also called mycogenic and is divided into 2 classes: exogenous, when the fungal allergen enters the body from the outside and endogenous in the presence of a focus of fungal infection in the body. Ebastin is the optimal drug of the group of H1-histamine receptor blockers of the II generation, has a high safety profile and a convenient dosing regimen. The efficacy of ebastin has been demonstrated in a number of clinical studies and observations.

Allergy, allergic rhinitis, antihistamines, ebastin, Espa-Bastin